Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Roselli

Showing results (71-80 of 164) with videos related to

Pageof 17
Sort By:
Journal of Personalized Medicine|December 29, 2022
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case SeriesGiovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, et al.
Immunological Investigations|March 19, 2020
Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central ItalyAnna Aureli, Angelica Canossi, Tiziana Del Beato, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 11, 2012
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot studyPatrizia Ferroni, Francesca Martini, Ilaria Portarena, et al.
Experimental Gerontology|July 19, 2014
Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopeniaClaudia Basile, David Della-Morte, Francesco Cacciatore, et al.
Oncoimmunology|September 14, 2016
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapyMario Roselli, Vincenzo Formica, Vittore Cereda, et al.
Medical Oncology (Northwood, London, England)|October 12, 2013
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)Vincenzo Formica, Vittore Cereda, Maria-Giovana di Bari, et al.
Cancer Treatment Reviews|September 16, 2023
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trialsGiovanni Maria Iannantuono, Elias Chandran, Charalampos S Floudas, et al.
Cancer|March 26, 2010
Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patientsPatrizia Ferroni, Mario Roselli, Antonella Spila, et al.
The Oncologist|March 24, 2022
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) GenotypingCristina Morelli, Vincenzo Formica, Elena Doldo, et al.
Oncology|August 30, 2005
Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancerPatrizia Ferroni, Antonella Spila, Francesca Martini, et al.
Pageof 17

Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Journal of Personalized Medicine|December 29, 2022
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case SeriesGiovanni Maria Iannantuono, Silvia Riondino, Stefano Sganga, et al.
Immunological Investigations|March 19, 2020
Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central ItalyAnna Aureli, Angelica Canossi, Tiziana Del Beato, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 11, 2012
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot studyPatrizia Ferroni, Francesca Martini, Ilaria Portarena, et al.
Experimental Gerontology|July 19, 2014
Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopeniaClaudia Basile, David Della-Morte, Francesco Cacciatore, et al.
Oncoimmunology|September 14, 2016
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapyMario Roselli, Vincenzo Formica, Vittore Cereda, et al.
Medical Oncology (Northwood, London, England)|October 12, 2013
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)Vincenzo Formica, Vittore Cereda, Maria-Giovana di Bari, et al.
Cancer Treatment Reviews|September 16, 2023
Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trialsGiovanni Maria Iannantuono, Elias Chandran, Charalampos S Floudas, et al.
Cancer|March 26, 2010
Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patientsPatrizia Ferroni, Mario Roselli, Antonella Spila, et al.
The Oncologist|March 24, 2022
Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) GenotypingCristina Morelli, Vincenzo Formica, Elena Doldo, et al.
Oncology|August 30, 2005
Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancerPatrizia Ferroni, Antonella Spila, Francesca Martini, et al.
Pageof 17